JP2021522344A - トレオン酸マグネシウム組成物及びその使用 - Google Patents

トレオン酸マグネシウム組成物及びその使用 Download PDF

Info

Publication number
JP2021522344A
JP2021522344A JP2021509954A JP2021509954A JP2021522344A JP 2021522344 A JP2021522344 A JP 2021522344A JP 2021509954 A JP2021509954 A JP 2021509954A JP 2021509954 A JP2021509954 A JP 2021509954A JP 2021522344 A JP2021522344 A JP 2021522344A
Authority
JP
Japan
Prior art keywords
dosage form
magnesium
threonic acid
day
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522344A5 (https=
Inventor
リュウ グオソン
リュウ グオソン
マオ フェイ
マオ フェイ
グレゴリー ワインガー ジェイソン
グレゴリー ワインガー ジェイソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocentria Inc
Original Assignee
Neurocentria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocentria Inc filed Critical Neurocentria Inc
Publication of JP2021522344A publication Critical patent/JP2021522344A/ja
Publication of JP2021522344A5 publication Critical patent/JP2021522344A5/ja
Priority to JP2024178890A priority Critical patent/JP2025011238A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021509954A 2018-04-25 2019-04-24 トレオン酸マグネシウム組成物及びその使用 Pending JP2021522344A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024178890A JP2025011238A (ja) 2018-04-25 2024-10-11 トレオン酸マグネシウム組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662756P 2018-04-25 2018-04-25
US62/662,756 2018-04-25
PCT/US2019/028903 WO2019209943A1 (en) 2018-04-25 2019-04-24 Magnesium threonate compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024178890A Division JP2025011238A (ja) 2018-04-25 2024-10-11 トレオン酸マグネシウム組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2021522344A true JP2021522344A (ja) 2021-08-30
JP2021522344A5 JP2021522344A5 (https=) 2022-04-28

Family

ID=68291941

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021509954A Pending JP2021522344A (ja) 2018-04-25 2019-04-24 トレオン酸マグネシウム組成物及びその使用
JP2024178890A Pending JP2025011238A (ja) 2018-04-25 2024-10-11 トレオン酸マグネシウム組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024178890A Pending JP2025011238A (ja) 2018-04-25 2024-10-11 トレオン酸マグネシウム組成物及びその使用

Country Status (9)

Country Link
US (2) US11717501B2 (https=)
EP (1) EP3784227A4 (https=)
JP (2) JP2021522344A (https=)
KR (1) KR20210005662A (https=)
CN (3) CN112384210A (https=)
AU (2) AU2019261406A1 (https=)
BR (1) BR112020021812A2 (https=)
CA (1) CA3098360A1 (https=)
WO (1) WO2019209943A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途
MY197760A (en) 2020-06-01 2023-07-13 Celagenex Res India Pvt Ltd Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
JP7805352B2 (ja) * 2020-08-28 2026-01-23 ディーエフアイ ユーエスエー，エルエルシー Ｌ－キシロン酸からｌ－トレオン酸塩を生産する方法
CN114304610A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有苏糖酸镁的营养补充剂及其应用
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug
CN119504413A (zh) * 2025-01-20 2025-02-25 浙江天启生化股份有限公司 一种l-苏糖酸镁合成方法及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531165A (ja) * 2000-04-19 2003-10-21 スミスクライン ビーチャム パブリック リミテッド カンパニー 組成物
JP2009137988A (ja) * 1997-04-11 2009-06-25 Abbott Lab エリスロマイシン誘導体の持続放出性配合薬
JP2010522216A (ja) * 2007-03-22 2010-07-01 リュー，グオソン マグネシウム組成物およびその使用
JP2011057683A (ja) * 2002-07-29 2011-03-24 Glaxo Group Ltd ラモトリギンを含む徐放性処方
CN105326955A (zh) * 2015-11-02 2016-02-17 北京市眼科研究所 一种治疗睑缘炎的组合物及其制备方法
CN106360734A (zh) * 2016-09-28 2017-02-01 张家港威胜生物医药有限公司 一种同时具有减肥和美容作用的组合物及其制备方法与用途
JP2017031189A (ja) * 2010-02-03 2017-02-09 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163301B2 (en) 2007-03-22 2012-04-24 Magceutics, Inc. Magnesium compositions and uses thereof for metabolic disorders
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
WO2017044486A1 (en) * 2015-09-11 2017-03-16 Neurocentria, Inc. Threonate compounds and methods of use thereof
CN105326855A (zh) * 2015-10-27 2016-02-17 南京大学 易吸收复合夹层式螯合镁钙片
US10617713B2 (en) * 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
CN107625776A (zh) * 2016-07-19 2018-01-26 无锡脑镁素生物医药科技有限公司 用于改善睡眠的镁组合物及其用途
WO2018200885A1 (en) * 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009137988A (ja) * 1997-04-11 2009-06-25 Abbott Lab エリスロマイシン誘導体の持続放出性配合薬
JP2003531165A (ja) * 2000-04-19 2003-10-21 スミスクライン ビーチャム パブリック リミテッド カンパニー 組成物
JP2011057683A (ja) * 2002-07-29 2011-03-24 Glaxo Group Ltd ラモトリギンを含む徐放性処方
JP2010522216A (ja) * 2007-03-22 2010-07-01 リュー，グオソン マグネシウム組成物およびその使用
JP2017031189A (ja) * 2010-02-03 2017-02-09 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
CN105326955A (zh) * 2015-11-02 2016-02-17 北京市眼科研究所 一种治疗睑缘炎的组合物及其制备方法
CN106360734A (zh) * 2016-09-28 2017-02-01 张家港威胜生物医药有限公司 一种同时具有减肥和美容作用的组合物及其制备方法与用途

Also Published As

Publication number Publication date
CN120168449A (zh) 2025-06-20
CN112384210A (zh) 2021-02-19
EP3784227A4 (en) 2022-03-02
AU2019261406A1 (en) 2020-12-17
US20240156761A1 (en) 2024-05-16
US11717501B2 (en) 2023-08-08
KR20210005662A (ko) 2021-01-14
AU2025201393A1 (en) 2025-03-20
BR112020021812A2 (pt) 2021-02-23
WO2019209943A1 (en) 2019-10-31
CA3098360A1 (en) 2019-10-31
JP2025011238A (ja) 2025-01-23
US20190328689A1 (en) 2019-10-31
CN120241690A (zh) 2025-07-04
EP3784227A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
JP2021522344A (ja) トレオン酸マグネシウム組成物及びその使用
US8895615B1 (en) Composition and method for treating neurological disease
JP5452236B2 (ja) ロウ様物質を用いた徐放性組成物
JP2022522270A (ja) 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
JPH0696524B2 (ja) バルプロ酸をベ−スとした新規薬剤組成物及びその製法
CN1187052C (zh) 含有司他夫定(stavudine)的持续释放微球
US4867987A (en) Pharmaceutical product for the sustained release of ibuprofen
KR20170115036A (ko) 특히 주의력 결핍 장애의 치료를 위한 방법 및 조성물
WO2014134221A1 (en) Compositions and methods for treatment in parkinson's disease patients
JPH05339151A (ja) 持効性塩酸オキシブチニン製剤
TW202123927A (zh) 多重顆粒醫藥組成物、立即釋放顆粒、緩釋顆粒、腸溶顆粒與其用途
TW202313072A (zh) 檸檬酸鐵之兒科調配物
KR20230124622A (ko) 레보도파 투여 요법
WO2001028516A2 (en) Sustained-release formulations for treating cns-mediated disorders
CN101756981A (zh) 一种布洛氯雷伪麻缓释制剂及其制备方法
WO2023244591A1 (en) Phloroglucinol formulations and methods of use
CN116801869A (zh) 左旋多巴给药方案

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240611